Search results
Results From The WOW.Com Content Network
Hydromorphone, also known as dihydromorphinone, and sold under the brand name Dilaudid among others, is a morphinan opioid used to treat moderate to severe pain. [7] Typically, long-term use is only recommended for pain due to cancer. [9] It may be used by mouth or by injection into a vein, muscle, or under the skin. [7]
Carbonate derivatives of 14β-hydroxycodeine "viz., 14β-hydroxy-6-O-(methoxycarbonyl)codeine, 6-O-methoxycarbonyl-14β-(methoxycarbonyloxy)codeine, and 14β-acetoxy-6-O-methoxy-carbonylcodeine, potential substrates for ring C modification in morphinane (sic) alkaloids, were synthesized for the first time."
Oxymorphone (sold under the brand names Numorphan and Opana among others) is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. [6]
The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse of the drug or other substances may lead to severe psychological or physical dependence. The complete list of Schedule II substances is as follows.
Any chemical substance with biological activity may be considered a drug. This list categorises drugs alphabetically and also by other categorisations. This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once.
Last October the FDA upgraded hydrocodone-containing drugs from a Schedule 3 to Schedule 2 controlled substance, "which would increase the controls on these products." Schedule 1 are drugs ...
Nearly 108,000 people died from drug overdoses in 2022, with approximately 82,000, or 76 percent, of those deaths stemming from opioid usage, according to the Center for Disease Control.
Knoll Pharmaceuticals was a drug development company founded by Albert Knoll and Hans Knoll in Germany in 1886. The company was taken over by German BASF in 1975, which sold it to Abbott Laboratories on 30 June 2002 for $6.9 billion. [1] [2] It was the developer of several drugs: